Literature DB >> 27217052

Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.

R M Zur1, L M Roy1, S Ito2,3, J Beyene4, C Carew5, W J Ungar1,6.   

Abstract

Thiopurine S-methyltransferase (TPMT) deficiency increases the risk of serious adverse events in persons receiving thiopurines. The objective was to synthesize reported sensitivity and specificity of TPMT phenotyping and genotyping using a latent class hierarchical summary receiver operating characteristic meta-analysis. In 27 studies, pooled sensitivity and specificity of phenotyping for deficient individuals was 75.9% (95% credible interval (CrI), 58.3-87.0%) and 98.9% (96.3-100%), respectively. For genotype tests evaluating TPMT*2 and TPMT*3, sensitivity and specificity was 90.4% (79.1-99.4%) and 100.0% (99.9-100%), respectively. For individuals with deficient or intermediate activity, phenotype sensitivity and specificity was 91.3% (86.4-95.5%) and 92.6% (86.5-96.6%), respectively. For genotype tests evaluating TPMT*2 and TPMT*3, sensitivity and specificity was 88.9% (81.6-97.5%) and 99.2% (98.4-99.9%), respectively. Genotyping has higher sensitivity as long as TPMT*2 and TPMT*3 are tested. Both approaches display high specificity. Latent class meta-analysis is a useful method for synthesizing diagnostic test performance data for clinical practice guidelines.The Pharmacogenomics Journal advance online publication, 24 May 2016; doi:10.1038/tpj.2016.37.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27217052      PMCID: PMC4957983          DOI: 10.1038/tpj.2016.37

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  57 in total

1.  Bayesian approaches to modeling the conditional dependence between multiple diagnostic tests.

Authors:  N Dendukuri; L Joseph
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Modeling conditional dependence between diagnostic tests: a multiple latent variable model.

Authors:  Nandini Dendukuri; Alula Hadgu; Liangliang Wang
Journal:  Stat Med       Date:  2009-02-01       Impact factor: 2.373

3.  Whole-blood thiopurine S-methyltransferase activity with genotype concordance: a new, simplified phenotyping assay.

Authors:  Loretta Ford; Valerie Graham; Jonathan Berg
Journal:  Ann Clin Biochem       Date:  2006-09       Impact factor: 2.057

4.  Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity.

Authors:  S Alves; A Amorim; F Ferreira; M J Prata
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

5.  Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis.

Authors:  C Spire-Vayron de la Moureyre; H Debuysère; N Sabbagh; D Marez; E Vinner; E D Chevalier; J M Lo Guidice; F Broly
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

6.  Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.

Authors:  Hua-Wen Xin; Hui Xiong; Xiao-Chun Wu; Qing Li; Lei Xiong; Ai-Rong Yu
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

Review 7.  Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae.

Authors:  Alison Sinclair; Xuanqian Xie; Marty Teltscher; Nandini Dendukuri
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

8.  Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?

Authors:  M Fakhoury; J Andreu-Gallien; A Mahr; Y Medard; S Azougagh; E Vilmer; E Jacqz-Aigrain
Journal:  J Clin Pharm Ther       Date:  2007-12       Impact factor: 2.512

9.  Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity.

Authors:  Loredana Serpe; Pier Luigi Calvo; Elisabetta Muntoni; Sergio D'Antico; Mario Giaccone; Alessandra Avagnina; Maurizio Baldi; Cristiana Barbera; Franco Curti; Angelo Pera; Mario Eandi; Gian Paolo Zara; Roberto Canaparo
Journal:  Pharmacogenomics       Date:  2009-11       Impact factor: 2.533

10.  Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis.

Authors:  Peter G Langley; James Underhill; J Michael Tredger; Suzanne Norris; Ian G McFarlane
Journal:  J Hepatol       Date:  2002-10       Impact factor: 25.083

View more
  2 in total

1.  The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.

Authors:  M M T J Broekman; D R Wong; G J A Wanten; H M Roelofs; C J van Marrewijk; O H Klungel; A L M Verbeek; P M Hooymans; H-J Guchelaar; H Scheffer; L J J Derijks; M J H Coenen; D J de Jong
Journal:  Pharmacogenomics J       Date:  2017-01-03       Impact factor: 3.550

Review 2.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.